Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 13, 2016 12:30 ET | Source: Genticel S.A.

Genticel Reports Final Results of GTL001 Phase 2 Trial in HPV16/18-Infected Women

No statistical difference in viral clearance between treatment and placebo groups at any time point over 2 yearsNo difference in incidence of subjects progressing to high-grade cervical lesions...
November 30, 2016 08:00 ET | Source: Genticel S.A.

GENTICEL successfully completes determining milestone in partnership with Serum Institute regarding use of GTL003 in multivalent vaccines

PARIS and TOULOUSE, France, Nov. 30, 2016 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative...
July 06, 2016 12:35 ET | Source: Genticel S.A.

Genticel Appoints Eumedix as Strategic Advisor to Support Company’s Access to Innovative Drug Candidates

PARIS and TOULOUSE, France, July 06, 2016 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative...
June 23, 2016 11:45 ET | Source: Genticel S.A.

Genticel Reports 18 Month Interim Analysis of GTL001 Phase 2 Trial in HPV16/18 Infected Women

No statistical difference seen between treatment and placebo GTL001 development plan is under review Strategic pipeline development activities remain on trackAgreement with Serum Institute of India on...
June 15, 2016 16:01 ET | Source: Genticel S.A.

Genticel to Present Clinical Results of GTL001 and Preclinical Results of GTL002 at EUROGIN 2016 Congress in Salzburg, Austria

PARIS and TOULOUSE, France, June 15, 2016 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative...
June 13, 2016 16:01 ET | Source: Genticel S.A.

Genticel Announces Completion of Two Major Milestones in Preparation for Phase 3 Program of GTL001

Ability to Use Clinically Validated hpv testsFive-Year Stability of GTL001 Drug Product PARIS and TOULOUSE, France, June 13, 2016 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels:...
June 01, 2016 13:10 ET | Source: Genticel S.A.

Genticel Announces Publication in ‘Clinical Cancer Research’ of Phase 1 Trial Results Supporting Safety, Tolerability and Immunogenicity of GTL001

PARIS and TOULOUSE, France, June 01, 2016 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative...
April 20, 2016 16:01 ET | Source: Genticel S.A.

Genticel Reports Additional Results at 12 Months From Phase 2 Trial of HPV Immunotherapeutic Candidate, GTL001

PARIS and TOULOUSE, France, April 20, 2016 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative...
March 14, 2016 09:21 ET | Source: Genticel S.A.

Genticel Announces 2015 Annual Results and Strategic Update for 2016

Cash position of € 21.8 million as at December 31, 2015First income from partnership with Serum Institute of India Ltd recorded in 2015Operating expenses in line with 2015 clinical milestonesStrategic...
January 27, 2016 13:22 ET | Source: Genticel S.A.

Genticel Reports Initial Results at 12 Months From Phase 2 Trial of HPV Immunotherapeutic Candidate, GTL001

12- month primary endpoint not met in the overall populationStatistical difference in viral clearance rates in 2 predefined key subgroups DSMB recommends continuation of the study per protocol18-month...

Next Page keyboard_arrow_right